Merus
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.About MRUS
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors.
CEOSven Ante Lundberg
CEOSven Ante Lundberg
Employees260
Employees260
HeadquartersUtrecht, Utrecht
HeadquartersUtrecht, Utrecht
Founded2003
Founded2003
Employees260
Employees260
MRUS Key Statistics
Market cap5.06B
Market cap5.06B
Price-Earnings ratio-12.08
Price-Earnings ratio-12.08
Dividend yield—
Dividend yield—
Average volume640.10K
Average volume640.10K
High today$69.26
High today$69.26
Low today$66.79
Low today$66.79
Open price$68.49
Open price$68.49
Volume634.80K
Volume634.80K
52 Week high$70.65
52 Week high$70.65
52 Week low$33.19
52 Week low$33.19
MRUS News
TipRanks 13h
Merus initiated with an Overweight at BarclaysBarclays initiated coverage of Merus (MRUS) with an Overweight rating and $112 price target The company’s Phase 3 clinical asset, petosemtamab, is being evaluat...
TipRanks 5d
Merus’s Oncology Potential and Financial Stability Justify Buy RatingAnalyst Charles Zhu from LifeSci Capital maintained a Buy rating on Merus and keeping the price target at $110.00. Elevate Your Investing Strategy: Take advanta...
Analyst ratings
100%
of 19 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.